SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Rithm Perpetual Life Residential Trust completed an unregistered sale of 610,891.013 common shares (Class J and Class E) for approximately $12.5 million on June 1, 2026, under Section 4(a)(2) and Regulation D Rule 506. This private placement increases share count and dilutes existing shareholders.
View raw filing on EDGAR →Ares Real Estate Income Trust entered into a subscription agreement on May 29, 2026, for Perigee SPV to purchase $100,000,000 of Class B common shares at NAV, and separately issued approximately $27.9 million in unregistered Class S-PR, Class D-PR, and Class I-PR shares pursuant to Regulation D exemption. These equity issuances, while exempt from registration, materially dilute existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →The filing discloses an unregistered sale of 36,771.87 common shares across multiple classes for approximately $750,000 in aggregate consideration, exempt under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement that increases share count and dilutes existing shareholders, material to investor assessment of ownership and capital structure.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Vontier's Annual Meeting held June 4, 2026. The filing reports voting outcomes on three proposals: election of seven directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from a Special Meeting held on June 3, 2026, reporting voting outcomes on four proposals including approval of an asset sale to Allbirds IP LLC, a charter amendment, issuance of shares upon convertible note conversion, and an adjournment proposal. The asset sale approval is particularly material as it represents a significant disposition of company assets. Item 5.07 explicitly governs shareholder vote results, and the filing directly reports the vote tallies and outcomes for each proposal.
View raw filing on EDGAR →Greenidge issued 1,162,221 shares of Class A Common Stock in exchange for $2,089,400 principal amount of 8.50% Senior Notes due October 2026 under Section 3(a)(9) exemption. This debt-for-equity exchange dilutes existing shareholders and signals financial stress as the company seeks to satisfy $33.1 million in remaining debt obligations through non-cash equity issuances rather than cash repayment.
View raw filing on EDGAR →Lyft held its annual meeting of stockholders on June 3, 2026, with shareholders voting on six proposals: election of three directors (David Risher, Deborah Hersman, Dave Stephenson), ratification of PricewaterhouseCoopers LLP as auditor, advisory votes on executive compensation and frequency thereof, and two amendments to the Restated Certificate of Incorporation. All proposals passed.
View raw filing on EDGAR →Stockholder-approved amendments to Lyft's Certificate of Incorporation (Proposals 5 and 6) became effective on June 3, 2026. The specific substantive nature of the amendments is not detailed in the 8-K Item 5.03 disclosure.
View raw filing on EDGAR →Globus Medical held its Annual Meeting of Stockholders and disclosed voting results on four proposals: election of two Class II directors (Keith W. Pfeil and Robert A. Douglas), approval of an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 1,000,000, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of 2025 named executive officer compensation.
View raw filing on EDGAR →iHeartMedia held its Annual Meeting on June 4, 2026, with shareholders voting on four proposals: election of eight directors, ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the Long-Term Incentive Award Plan. All voting results were disclosed with detailed vote tallies.
View raw filing on EDGAR →The filing discloses Samsara Inc.'s financial results for the three months ended May 2, 2026, via a press release attached as Exhibit 99.1. This is a standard quarterly earnings release disclosed under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Figma's June 2, 2026 annual meeting of stockholders. The filing reports final vote tallies for two proposals: (1) election of eight directors, with detailed vote counts for each nominee, and (2) ratification of Ernst & Young LLP as independent auditor. This is a textbook Item 5.07 disclosure and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →Wealthfront Corporation disclosed financial results for the first fiscal quarter ended April 30, 2026, via a press release furnished as Exhibit 99.1, with a scheduled conference call to discuss results.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from GoPro's June 2, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports voting outcomes on five proposals: election of seven directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on executive compensation, approval of 13 million additional shares under the 2024 Equity Incentive Plan, and approval of convertible debenture issuance under Nasdaq Rule 5635(d). All proposals passed with substantial majorities, and the disclosure includes detailed vote tallies for each nominee and proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Hinge Health's June 3, 2026 Annual Meeting of Stockholders. The filing reports final vote tallies for two proposals: (1) election of Class I directors Teddie Wardi and Tyler Sloat, and (2) ratification of Deloitte & Touche LLP as independent auditor. Both proposals passed with substantial majorities. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →BioMarin held its Annual Meeting of stockholders on June 4, 2026, with stockholders voting on four proposals: election of ten directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2017 Equity Incentive Plan increasing the share reserve by 7,650,000 shares. All four proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Axalta's June 3, 2026 Annual General Meeting. The filing reports voting outcomes on three matters: election of nine directors, appointment of PricewaterhouseCoopers LLP as auditor, and Say on Pay approval for 2025 named executive officers. The detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each matter are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →Cooper Companies issued a press release on June 4, 2026 reporting financial results for its fiscal second quarter ended April 30, 2026.
View raw filing on EDGAR →Cooper Companies disclosed a material litigation settlement related to a December 2023 recall of CooperSurgical's LifeGlobal embryo culture media, accruing $271.6 million in net litigation liabilities (after insurance recoveries) to resolve over 95% of more than 1,500 claimants across 140+ lawsuits and three putative class actions.
View raw filing on EDGAR →While filed under Item 3.02 (Unregistered Sales of Equity Securities), the core disclosure is entry into an Agreement and Plan of Merger to acquire 100% of Astrobotic Technology, Inc., with closing expected in H2 2026. The unregistered share issuance is merely the consideration mechanism for this material acquisition. This is a change-of-control transaction that would materially affect investor assessment of the registrant.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results under Item 5.07. The filing reports the results of a special meeting held on June 4, 2026, where stockholders voted on a Reincorporation Proposal to convert the company from Delaware to Nevada incorporation. The vote tally shows 171,505,308 votes for (59.2%), 96,295,425 against (33.2%), and 147,411 abstentions, with the proposal approved. A reincorporation is a material corporate governance event affecting the registrant's legal structure and jurisdiction.
View raw filing on EDGAR →Abacus Global Management held its Annual Meeting on June 3, 2026, and disclosed voting results for five proposals: election of Class III directors (Jay Jackson and Thomas W. Corbett, Jr.), ratification of KPMG LLP as independent auditor, approval of the 2026 Long-Term Equity Incentive Plan, advisory vote on executive compensation, and advisory vote on Say-on-Pay frequency.
View raw filing on EDGAR →TIC Solutions entered into a Third Amendment to its Credit Agreement on June 2, 2026, which reduced interest rates by 25 basis points and increased the Letter of Credit Sublimit to $50 million. This material modification to the Company's debt structure affects borrowing costs and credit availability.
View raw filing on EDGAR →The filing discloses two material debt-related transactions: (1) an expected amendment to the Credit Agreement to extend maturity of $848 million in term loans to 2033, reduce pricing, and upsize by $353 million, and (2) a partial redemption of $350 million of the $550 million outstanding 2028 Notes at par plus accrued interest, conditioned on refinancing proceeds. While these are significant capital structure events affecting the company's debt profile and financial obligations, they do not fit cleanly into the specific covenant_breach, ma_activity, or dilutive_issuance categories—they represent refinancing and debt management activities that would materially affect a reasonable investor's assessment of the company's leverage and liquidity position.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final voting results from Evolent Health's 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing presents detailed vote tallies for four proposals: election of ten directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2015 Omnibus Incentive Compensation Plan. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Rimini Street's June 3, 2026 Annual Meeting of Stockholders on three proposals: election of three Class III directors, a non-binding say-on-pay vote, and ratification of KPMG LLP as independent auditor. The tabulated vote counts for each proposal are the core content, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →Health Catalyst entered into a Unit Purchase Agreement to sell all equity interests of its Vitalware Business to Med-Metrix, LLC for a base purchase price of $147 million, with expected closing in Q3 2026 and proceeds earmarked to repay the company's senior secured term loan facility.
View raw filing on EDGAR →ServiceTitan issued a press release on June 4, 2026 announcing financial results for the fiscal first quarter ended April 30, 2026, with a conference call scheduled to discuss these results. This is a standard quarterly earnings release disclosure under Item 2.02, with the press release furnished as Exhibit 99.1. Quarterly financial results are material to investors' assessment of the company's operational performance.
View raw filing on EDGAR →Smith-Midland received a notice from Nasdaq on May 29, 2026 stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file the Form 10-Q for the quarter ended March 31, 2026. While the notice has no immediate delisting effect, the company faces a July 28, 2026 deadline to file or submit a compliance plan, creating material delisting risk. This is a classic Item 3.01 disclosure of failure to satisfy a continued listing rule.
View raw filing on EDGAR →This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of New York. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the prose does not disclose a specific new debt issuance event with quantified amounts or dates—rather, it provides regulatory framework and general disclosure methodology. The actual Schedule A referenced would contain the material details, but those specifics are not included in this section. This appears to be a standing disclosure about the Bank's debt issuance program rather than a discrete material event, making it difficult to classify under the more specific event types; accordingly, `other_material` is most appropriate.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from TSS, Inc.'s annual meeting held on June 4, 2026. The filing reports final voting tallies for two proposals: (1) election of Class III directors (Peter Woodward and Vivek Mohindra) and (2) ratification of BDO USA, P.C. as independent auditor. This directly matches Item 5.07 and the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 4, 2026, filed under Item 5.07. The filing reports voting outcomes for three proposals: election of nine directors, advisory vote on executive compensation, and ratification of Deloitte LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and shareholder approval of key corporate matters.
View raw filing on EDGAR →This is a clear auditor change under Item 4.01. Assure CPA, LLC resigned as the independent registered public accounting firm on June 2, 2026, following its merger into Sadler, Gibb & Associates, and Sadler was appointed as the successor auditor on June 3, 2026. The filing explicitly documents the resignation, the reason (merger), and the appointment of the replacement auditor, with confirmations that there were no disagreements or reportable events during the prior two fiscal years.
View raw filing on EDGAR →iQSTEL entered into a binding Memorandum of Understanding on June 3, 2026 to acquire a 51% controlling interest in Ultranet Telecom Group for US$17.6 million, significantly expanding the Company's revenue by approximately US$130 million annually and pushing it above a US$500 million annualized revenue run rate.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Bioventus's 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports voting outcomes for director elections (12 nominees) and ratification of Grant Thornton LLP as independent auditor, with detailed vote tallies (For, Withheld, Broker Non-Votes). This is the quintessential shareholder_vote_results event under Item 5.07, and is material as it documents the composition of the Board of Directors and auditor appointment.
View raw filing on EDGAR →Atkore entered into a $50 million settlement agreement on June 3, 2026 with the End User Plaintiffs in the In re PVC Pipe Antitrust Litigation, resolving claims related to alleged coordinated conduct in the PVC pipe and conduit industry. The settlement is material to investors as it resolves significant antitrust litigation exposure, reduces legal uncertainty, and will be recorded as a non-operating expense in Q2 2026, though the company states it is not expected to materially impact liquidity or leverage metrics.
View raw filing on EDGAR →The disclosure reports a Board-committed plan to close a manufacturing facility in the Netherlands with expected pre-tax charges of $80–110 million, primarily from asset write-downs, inventory charges, and employee severance. While this is a material restructuring event affecting future financial results, it does not fit cleanly into the "material_impairment" category (which typically covers asset write-downs already recognized) or any other specific taxonomy event. The charges are prospective and tied to an exit/disposal activity, making "other_material" the most appropriate classification for this significant operational restructuring.
View raw filing on EDGAR →The filing discloses authorization and declaration of quarterly dividends on both common stock ($0.01 per share) and preferred stock ($0.484375 per share), with specific payment and record dates. While dividend declarations are routine corporate actions, they are material to shareholders as they affect distributions and are typically disclosed in 8-K filings. This does not fit the more specific earnings_release category (which typically involves financial results) nor any other defined event type, making other_material the appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from RadNet's June 2, 2026 Annual Meeting of Stockholders. The filing reports final certified voting results for four proposals: election of six directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and approval of an amended Equity Incentive Plan. This is the quintessential Item 5.07 disclosure and is material to investors as it confirms governance outcomes and executive compensation arrangements.
View raw filing on EDGAR →The filing discloses an At Market Offering (ATM) agreement under which Aethlon Medical may offer and sell up to $542,716 of additional common stock pursuant to an amended prospectus supplement. This represents a dilutive equity issuance registered under Form S-3, with shares eligible for sale in the public market. The company had previously sold $1,849,457 of shares under the same ATM agreement, demonstrating active capital raising through equity dilution.
View raw filing on EDGAR →iPower announced completion of a ~$1 million purchase of USDai cryptocurrency and plans to stake it into sUSDai as part of an "AI infrastructure investment strategy." This represents a material capital deployment into digital assets that would affect investor assessment of the company's strategic direction and asset composition, but does not fit neatly into standard M&A, impairment, or other predefined categories. The company's explicit 8-K filing and press release signal materiality despite the non-traditional asset class.
View raw filing on EDGAR →The filing discloses a settlement agreement between Invech Holdings and Arnold F. Sock involving the issuance of IVHI shares to settle a balance due. While Item 1.01 typically covers M&A activity, this settlement agreement does not constitute a material acquisition, disposition, merger, or change of control. The transaction involves share issuance to settle a liability, which could be characterized as a dilutive issuance, but the primary focus is on settling an existing obligation rather than raising capital. The materiality of the settlement and the share issuance warrants disclosure, but the event does not cleanly fit the standard M&A taxonomy.
View raw filing on EDGAR →The filing discloses that the Android version of SafeDeal Connect, the Company's core mobile application, was removed from the Google Play Store and remains unavailable. This represents a material disruption to the Company's primary product offering and user accessibility, affecting a significant portion of the mobile user base. While the Company is working to restore availability, the inability to provide a definitive restoration timeline due to Google's review process creates material uncertainty about product availability and revenue impact.
View raw filing on EDGAR →Z Squared Inc. entered into a Committed Equity Forward Purchase Agreement with LucentHash / Data Part Capital allowing the sale of up to $50 million in common stock over 18 months at the Company's discretion. The unregistered private placement is issued under Section 4(a)(2) exemption with the purchaser restricted to 19.99% ownership, creating significant dilution risk and signaling potential capital needs.
View raw filing on EDGAR →The company executed a 1-for-500 reverse stock split, effective June 5, 2026, reducing outstanding shares from approximately 20.2 billion to approximately 40.4 million. The reverse split was approved by the Board and shareholders and was accompanied by a name change and trading symbol change.
View raw filing on EDGAR →This is a standard Item 5.07 disclosure of shareholder meeting results held on June 4, 2026. The filing reports voting outcomes for three proposals: election of seven directors (all approved), ratification of Haynie & Company as independent auditor (approved), and approval of an amendment to the 2022 equity incentive plan (approved). The disclosure includes vote tallies (For, Against/Withheld, Abstain, Broker Non-Votes) for each proposal, which is the core content of shareholder_vote_results.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the June 2, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: (i) election of six directors to the Board, (ii) advisory approval of named executive officer compensation, and (iii) ratification of Grant Thornton LLP as independent auditor. Detailed vote tallies (votes for, withheld, against, abstentions, and broker non-votes) are provided for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Denali Therapeutics' June 3, 2026 annual meeting of stockholders, including voting outcomes on three proposals: election of three Class III directors (with specific vote tallies for each nominee), ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation. The filing directly matches the shareholder_vote_results event type and is material to investors assessing board composition and governance.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of three matters voted upon at Gossamer Bio's Annual Meeting of stockholders: (1) election of two Class II directors (Faheem Hasnain and Russell Cox), (2) ratification of Ernst & Young LLP as independent auditor, and (3) advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are the hallmark of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →Gossamer Bio entered into material definitive agreements on June 4, 2026, including a New Convertible Notes Indenture, Purchase Warrant Agreement, and Prefunded Warrants, representing a material capital restructuring involving conversion of existing convertible notes into new securities with warrants and equity raises contingent on FDA approval. The company simultaneously terminated its existing convertible notes through an exchange offer (90.526% of outstanding notes cancelled) and a Transaction Support Agreement. This comprehensive debt exchange and refinancing transaction materially affects the company's financial obligations and control structure.
View raw filing on EDGAR →